CliffBio
biologic

Evkeeza

evinacumab-dgnb

Loss of exclusivityFebruary 2033projected — 12-year biologic exclusivity estimate
CompanyRegeneron Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameEvkeeza
Active ingredientevinacumab-dgnb
Strength1,200MG/8ML (150MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2021
Marketing statusRx

More from Regeneron Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Evkeeza patent cliff — loss of exclusivity February 2033 | CliffBio